Form 4: Staffan Encrantz Increases Stake in Sight Sciences Through Multiple Transactions

Staffan Encrantz, a director and 10% owner of Sight Sciences, Inc., has increased his stake in the company through a series of open market purchases.

Summary

• Staffan Encrantz, a director and 10% owner of Sight Sciences, Inc. (SGHT), has reported changes in beneficial ownership.
• Between March 10, 2025, and March 12, 2025, Encrantz acquired a total of 513,000 shares of common stock through Allegro Investment Fund, L.P.
• The purchases were made in multiple transactions at weighted average prices ranging from $2.53 to $2.77 per share.
• Following these transactions, Encrantz indirectly owns 5,086,920 shares through Allegro Investment Fund, L.P.
• Encrantz also directly owns 1,029,516 shares of common stock, including 17,366 restricted stock units.
• Encrantz disclaims beneficial ownership of shares held by Allegro Investment Fund, L.P. and the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's prospects. However, the filing itself is a routine regulatory disclosure.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders.

Stakeholder Impact

• The increased stake by a director could positively influence shareholder sentiment.

Key Dates